Imaging chronic active lesions in multiple sclerosis: a consensus statement
VA Tennessee Valley Healthcare System · Nashville VA Medical Center · +34 more institutions
Abstract
Chronic active lesions (CAL) are an important manifestation of chronic inflammation in multiple sclerosis and have implications for non-relapsing biological progression. In recent years, the discovery of innovative MRI and PET-derived biomarkers has made it possible to detect CAL, and to some extent quantify them, in the brain of persons with multiple sclerosis, in vivo. Paramagnetic rim lesions on susceptibility-sensitive MRI sequences, MRI-defined slowly expanding lesions on T1-weighted and T2-weighted scans, and 18-kDa translocator protein-positive lesions on PET are promising candidate biomarkers of CAL. While partially overlapping, these biomarkers do not have equivalent sensitivity and specificity to…
Citation impact
- FWCI
- 60.91
- Percentile
- 100%
- References
- 190
Authors
21- FBFrancesca BagnatoCorresponding
VA Tennessee Valley Healthcare System, Nashville VA Medical Center, Cognitive Neuroimaging Lab, Institute of Neuroimmunology of the Slovak Academy of Sciences, Vanderbilt University Medical Center
- PSPascal Sati
Cedars-Sinai Medical Center
- CCChristopher C. Hemond
University of Massachusetts Chan Medical School
- CEColm Elliott
NeuroRx Research (Canada)
- SASusan A. Gauthier
Cornell University, Weill Cornell Medicine
Topics & keywords
- Multiple sclerosis
- Consensus conference
- Medicine
- Statement (logic)
- Pathology
- Psychiatry
- Internal medicine
- Political science
Funding
- UDU.S. Department of DefenseAwards: MS210103, W81XWH, K23NS126718, RG-2110-38460
- NMNational Multiple Sclerosis SocietyAwards: RG-1802-30140, PP-1809-32498, RFA-2203-39325, RG-1802-30468, AWD-00005884, R01 NS104283, RG-1901-33190, JF-2008-36971
- CNConrad N. Hilton FoundationAward: 17313
- ELEli Lilly and Company
- SSanofi
- CHCraig H. Neilsen Foundation
- BBiogen
- POPatient-Centered Outcomes Research InstituteAwards: RG-1902-33619, R21 NS129197, SI-2004-36589, R01 NS118886, R01 NS102267, W81XWH2110787, R01 NS112907, MS-1610-37115, W81XWH2010580, MS-1610-37047
- UOUniversity of Pennsylvania
- UOUniversity of Pittsburgh
- FBFondation Brain CanadaAwards: R56 NR019306-01A1, 1U01NS116776-01, U01 NS116776-01, R35 NS097303
- MRMyelin Repair FoundationAwards: R01 NS104283, R01 105144
- ABAtara BiotherapeuticsAwards: RG-1707-28775, W81XWH-14-1-0493
- IPInternational Progressive MS AllianceAward: PA-2107-38081
- HTHorizon Therapeutics
- MSMultiple Sclerosis Society of Canada
- MSMultiple Sclerosis Society
- FCFondazione CariploAwards: 2019–1677, 2019-1677
- CDCentre d'Imagerie BioMédicale
- IPIdorsia Pharmaceuticals
- ICInternational Collaboration on Repair DiscoveriesAwards: R01DA047088-01, 1R21NS1226737-01, 1R21NS123419-01, RG-1802-30468
- FRFondazione Regionale per la Ricerca BiomedicaAward: 1750327
- NINational Institutes of HealthAwards: R01NS082347, R21 NS116434-01A1, R35NS097303, KL2TR001454, R01 NS102267, R01 NS060910, NS003119, U01NS116776, R01 NS, NS097303, U01NS116776-01, W81XWH, RG-1901, R01 NS104283, R01DA047088, 1R21NS123419-01, RG-1901-33190, NS060910, 33190, 1R01NS104403-01, 1U01NS116776-01
- GGenentech
- ESEMD Serono
- PSPerelman School of Medicine, University of Pennsylvania
- UAUniversity at Buffalo
- PBPrincipia Biopharma
- NSNatural Sciences and Engineering Research Council of Canada
- NINational Institute of Neurological Disorders and StrokeAwards: R01 NS060910, Z01 NS003119, NS060910, K23NS126718, R35 NS097303, 1U01NS116776-01, R01NS082347, 1R01NS104403-01, NS097303
- NCNational Center for Advancing Translational SciencesAward: KL2TR001454
- JPJanssen Pharmaceuticals